Hiroshima University, Japan
Masaru Kunimoto was graduated from Wakayama Medical College in 1987 and completed his PhD in 1994. He has presented many studies about upper respiratory diseases, focal infection on tonsil, cancer related Epstein-Barr virus and immune response analysis using molecular biological technique. He has had an office in Hiroshima city since 2004 and is currently a Former Chairperson of Asa Otolaryngology and Member of Management Committee of Hiroshima Otolaryngology.
In 2014, an update to a meta-analysis of heptavalent pneumococcal conjugate vaccine (PCV7) effects on acute otitis media (AOM) was reported in the Cochrane collection and one of major conclusion was that the PCV7 had modest beneficial effects in terms of changes in AOM episodes and total number of visits to medical institutions by children. We have same results in Japanese children using the Japan Medical Data Center Claims Database. The Japanese guidelines for AOM in children recommend classifying AOM by age, manifestations and local findings. Myringotomy is recommended for moderate-grade cases with severe local findings, severe-grade cases and treatment resistant cases. We have previously conducted a retrospective multicenter study in the Asa Area of Hiroshima City, Japan to investigate changes in the number of myringotomies performed to treat AOM after public funded inoculation. The myringotomy rate per child-year in <5 year old children decreased by 29.1% in 2011 and by 25.2% in 2012 compared to the mean rate performed in the 3 years prior to the introduction of public funding in the multicenter study. Our results suggest the public benefit of PCV7 in reducing the AOM morbidity with less financial burden of myringotomy. In addition, this vaccine may help prevent AOM from aggravation with severe clinical manifestations. We will present the next data about this hypothesis.